Results 41 to 50 of about 1,066 (152)

An animal model of differential genetic risk for methamphetamine intake

Frontiers in Neuroscience, 2015
The question of whether genetic factors contribute to risk for methamphetamine (MA) use and dependence has not been intensively investigated. Compared to human populations, genetic animal models offer the advantages of control over genetic family history
Tamara ePhillips, Tamara ePhillips, Shkelzen eShabani   +2 more
doaj   +1 more source

Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays

Pharmaceuticals, 2023
Trace amine-associated receptor 1 (TAAR1) is an attractive target for the design of innovative drugs to be applied in diverse pharmacological settings. Due to a non-negligible structural similarity with endogenous ligands, most of the agonists developed ...
Elena Cichero, Valeria Francesconi, Beatrice Casini, Monica Casale, Evgeny Kanov, Andrey S. Gerasimov, Ilya Sukhanov, Artem Savchenko, Stefano Espinoza, Raul R. Gainetdinov, Michele Tonelli   +10 more
doaj   +1 more source

Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists.

PLoS ONE, 2011
Trace amine-associated receptors (TAAR) are rhodopsin-like G-protein-coupled receptors (GPCR). TAAR are involved in modulation of neuronal, cardiac and vascular functions and they are potentially linked with neurological disorders like schizophrenia and ...
Gunnar Kleinau, Juliane Pratzka, Daniela Nürnberg, Annette Grüters, Dagmar Führer-Sakel, Heiko Krude, Josef Köhrle, Torsten Schöneberg, Heike Biebermann   +8 more
doaj   +1 more source

Behavioral Effects of a Potential Novel TAAR1 Antagonist

Frontiers in Pharmacology, 2018
The trace amine associated receptor 1 (TAAR1) is a G-protein coupled receptor expressed in the monoaminergic regions of the brain, and represents a potential novel therapeutic target for the treatment of neurological disorders.
Vincent M. Lam, Catharine A. Mielnik, Corey Baimel, Pieter Beerepoot, Pieter Beerepoot, Stefano Espinoza, Ilya Sukhanov, Ilya Sukhanov, Wendy Horsfall, Raul R. Gainetdinov, Stephanie L. Borgland, Amy J. Ramsey, Ali Salahpour   +12 more
doaj   +1 more source

Study on Trace Amine-associated Receptor 1 (TAAR1) Ligand Neuron, D-neuron

International Journal of Biology and Pharmacy Research Archive, 2021
The latest psychopharmacological study showed effectiveness of a novel non-D2-receptor-binding drug, SEP-363856, for the treatment of schizophrenia. The compound is trace amine-associated receptor 1 (TAAR1) full agonist and also 5-hydroxytryptamin 1A (5-HT 1A) receptor partial agonist.
openaire   +2 more sources

Genetic Polymorphisms Affect Mouse and Human Trace Amine-Associated Receptor 1 Function.

PLoS ONE, 2016
Methamphetamine (MA) and neurotransmitter precursors and metabolites such as tyramine, octopamine, and β-phenethylamine stimulate the G protein-coupled trace amine-associated receptor 1 (TAAR1).
Xiao Shi, Nicole A R Walter, John H Harkness, Kim A Neve, Robert W Williams, Lu Lu, John K Belknap, Amy J Eshleman, Tamara J Phillips, Aaron Janowsky   +9 more
doaj   +1 more source

Incretin-like effects of small molecule trace amine-associated receptor 1 agonists

Molecular Metabolism, 2016
Objective: Type 2 diabetes and obesity are emerging pandemics in the 21st century creating worldwide urgency for the development of novel and safe therapies.
Susanne Raab, Haiyan Wang, Sabine Uhles, Nadine Cole, Ruben Alvarez-Sanchez, Basil Künnecke, Christoph Ullmer, Hugues Matile, Marc Bedoucha, Roger D. Norcross, Nickki Ottaway-Parker, Diego Perez-Tilve, Karin Conde Knape, Matthias H. Tschöp, Marius C. Hoener, Sabine Sewing   +15 more
doaj   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, Volume 183, Issue 14, Page 3897-3919, July 2026.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment

Frontiers in Psychiatry
For over seven decades, dopamine receptor 2 (D2 receptor) antagonists remained the mainstay treatment for neuropsychiatric disorders. Although it is effective for treating hyperdopaminergic symptoms, it is often ineffective for treating negative and ...
Britto Shajan, Tarun Bastiampillai, Tarun Bastiampillai, Shane D. Hellyer, Pramod C. Nair, Pramod C. Nair, Pramod C. Nair, Pramod C. Nair   +7 more
doaj   +1 more source

Trace Amine-Associated Receptor 1 Agonist Modulates Mismatch Negativity-Like Responses in Mice

Frontiers in Pharmacology, 2019
The trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor widely expressed in the mammalian brain, particularly in limbic system and monoaminergic areas.
Aleksander A. Aleksandrov, Veronika M. Knyazeva, Anna B. Volnova, Elena S. Dmitrieva, Nadezhda V. Polyakova, Raul R. Gainetdinov   +5 more
doaj   +1 more source